drugset / Trial / NCT04263350

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

NCT04263350

Phase 1 Completed 34 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare the amount of Atazanavir (ATV) and Cobicistat (COBI) in the bodies of healthy adult participants when taken as a combination formulation, and when ATV is administered as an oral powder at the same time as COBI administered as an oral tablet. The ATV/COBI combination formulation and ATV powder will be taken with food.

Timeline

Start
2020-02-26
Primary completion
2020-11-12
Completion
2020-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified Oral
Subject Cobicistat Small molecule Oral

Indications

No indication recorded.